Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
2005 · New England Journal of Medicine · 840 citations
https://doi.org/10.1056/nejmoa035717
K
Klemens Budde
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
971
Papers
33.8K
Citations
89
h-index
468
i10-index
Klemens Budde is an academic researcher from Charité - Universitätsmedizin Berlin. The author has contributed to research in topics: Renal Transplantation Outcomes and Treatments & Organ Transplantation Techniques and Outcomes & Organ Donation and Transplantation. The author has an h-index of 89, co-authored 826 publications.
ORCID: 0000-0002-7929-5942Papers by this author
worksA Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
2020 · Journal of the American Society of Nephrology · 168 citations
https://doi.org/10.1681/asn.2020071106
Therapeutic Drug Monitoring of Everolimus
2016 · Therapeutic Drug Monitoring · 131 citations
https://doi.org/10.1097/ftd.0000000000000260
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
2024 · New England Journal of Medicine · 127 citations
https://doi.org/10.1056/nejmoa2400763
UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients
2009 · Clinical Pharmacology & Therapeutics · 118 citations
https://doi.org/10.1038/clpt.2009.83
Quality of Life of Living Kidney Donors in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 Questionnaires
2004 · Transplantation · 113 citations
https://doi.org/10.1097/01.tp.0000133307.00604.86
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat